BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesPRNewsWire • 11/20/23
BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesPRNewsWire • 10/31/23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity InvestmentPRNewsWire • 10/12/23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)PRNewsWire • 09/28/23
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic CancerPRNewsWire • 09/19/23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaPRNewsWire • 09/11/23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesPRNewsWire • 08/30/23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate MotixafortidePRNewsWire • 07/17/23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesPRNewsWire • 05/24/23